Therefore, we hypothesized that the upregulation of PD-L1 on the BMDCs provided a target for anti–PD-1 or anti–PD-L1 therapy and that checkpoint blockade can further enhance the effect of EVs in a longer tumor model. This evidence concerns the gene PDCD1 and neoplasm.